Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells 5,354 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 5,354 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $83,361.78. Following the transaction, the insider owned 138,983 shares of the company’s stock, valued at approximately $2,163,965.31. This represents a 3.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

KalVista Pharmaceuticals Trading Up 1.3%

Shares of KALV stock traded up $0.21 on Tuesday, hitting $15.77. The stock had a trading volume of 751,567 shares, compared to its average volume of 635,299. The company’s 50 day moving average price is $15.47 and its 200-day moving average price is $13.94. KalVista Pharmaceuticals, Inc. has a 1 year low of $9.23 and a 1 year high of $19.00. The firm has a market capitalization of $797.17 million, a P/E ratio of -3.99 and a beta of -0.19. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21.

Analyst Upgrades and Downgrades

Several research firms recently commented on KALV. Needham & Company LLC boosted their target price on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. HC Wainwright lifted their price target on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Citizens Jmp reduced their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research note on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Finally, TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, KalVista Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $29.40.

Institutional Trading of KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of KALV. Tudor Investment Corp ET AL purchased a new stake in shares of KalVista Pharmaceuticals in the third quarter valued at $24,360,000. Vestal Point Capital LP increased its position in shares of KalVista Pharmaceuticals by 152.0% in the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock worth $30,524,000 after acquiring an additional 1,140,000 shares in the last quarter. Parkman Healthcare Partners LLC raised its holdings in shares of KalVista Pharmaceuticals by 155.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after buying an additional 1,055,940 shares during the period. Ameriprise Financial Inc. lifted its holdings in KalVista Pharmaceuticals by 2,258.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock worth $10,685,000 after buying an additional 905,053 shares in the last quarter. Finally, Elmind Capital LP acquired a new position in shares of KalVista Pharmaceuticals in the 4th quarter valued at approximately $12,941,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.